- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01590823
An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients
Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The frequency of atrial fibrillation (AF) is 10- to 20- fold higher in patients with end stage renal disease (ESRD) compared to the general population (1-5). Conditions contributing to the risk of stroke in AF are highly prevalent in ESRD patients undergoing dialysis (6). A large number of trials have shown the usefulness of oral anticoagulation with warfarin sodium for primary and secondary prevention of stroke in patients with AF (7). Despite that the majority of these trials excluded patients with ESRD, warfarin sodium is commonly prescribed in dialysis patients with AF for prevention of stroke (8). Managing dialysis patients on wafarin sodium is challenging given the plethora of drug and food interactions, need for frequent coagulation monitoring and dose adjustment and lack of large randomized clinical trails assessing the benefit of stroke prevention versus risk of hemorrhage in this population (8,9). Additionally, recent concern regarding the association between vascular calcification enhanced by warfarin sodium in dialysis patients highlights the need for alternative oral anticoagulant therapy (10,11).
A new oral anticoagulant, dabigatran etexilate, which is a direct thrombin inhibitor, has been approved for prevention of stroke in patients with AF and prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip and knee replacement surgeries(12-15). Other indications under investigation include the treatment of VTE (16) and the treatment of thromboembolic complications following acute coronary syndromes (17).
Dabigatran etexilate is an orally administered prodrug, which is rapidly absorbed and converted to its active form, dabigatran. Dabigatran specifically and reversibly inhibits thrombin which is a key enzyme required in the coagulation pathway. Dabigatran etexilate posses beneficial properties including: a fixed oral dosage regimen, predictable pharmacokinetic profile, strong association between plasma drug concentration and anticoagulation response, low potential for drug interactions and lack of need for routine coagulation monitoring (18-24). As such, dabigatran etexilate represents a possible improved alternative to warfarin for anticoagulation in dialysis patients with AF.
Dabigatran etexilate has been developed using a fixed dosage regimen of 150 mg twice daily in AF patients with normal renal function for prevention of stroke (12). Limited information regarding dosing dabigatran etexilate in patients with renal impairment or ESRD exists as these patients were excluded from all phase III trials. Despite this, a recent small study investigated the pharmacokinetics of a single oral dose of dabigatran etexilate 150 mg in healthy patients and in patients with mild to severe renal impairment (creatinine clearance >50 to ≤80 , >30 to ≤50 and <30 mL/min) and dabigatran etexilate 50 mg in patients with ESRD requiring maintenance hemodialysis (25).
Systemic exposure to dabigatran and corresponding coagulation response was increased by renal impairment and correlated with the severity of renal dysfunction suggesting that a reduced dose and or extended dose interval may be necessary in patients with mild to severe renal impairment. In the six patients that were studied, hemodialysis removed on average 62% and 68% of the dabigatran entering the dialyzer indicating that hemodialysis can compensate for the impaired dabigatran renal elimination that occurs in ESRD. Unfortunately, a meaningful correlation between dabigatran plasma concentrations and anticoagulation activity could not be determined as the hemodialysis patients were on unfractionated heparin to prevent clotting in their dialysis circuit. Furthermore, the necessity of a post-dialysis dose to maintain dabigatran levels in the therapeutic range was not investigated.
Herein, we propose a pilot study to examine the single dose pharmacokinetics and pharmacodynamics of dabigatran etexilate in hemodialysis patients who are receiving normal saline flushes for prevention of extracorporeal circuit clotting. The specific objective is to establish baseline correlation between plasma dabigatran concentrations versus anticoagulation activity over time. Our long-term objective is to develop an evidence-based recommendation for dabigatran dosing in hemodialysis patients.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, b3h 2y9
- Capital Health District Authority, Department of Medicine, Division of Nephrology
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients between 18 and 75 years receiving hemodialysis at the Capital District Health Authority Renal Program who are receiving or who are good candidates for normal saline flushes for prevention of extracorporeal circuit clotting will be eligible for this study.
Exclusion Criteria:
Of those fulfilling the inclusion criterion, the following will be excluding characteristics:
- know bleeding diathesis;
- geographic inaccessibility for follow-up of timed blood sampling;
- use of any anticoagulant drugs that might influence results within 48 hours of the study;
- history of allergy/hypersensitivity (including drug allergy) deemed relevant to the trial by the investigators;
- recent or planned diagnostic or therapeutic procedures with potential for bleeding within 14 days before or after drug administration;
- history of familial bleeding disorder;
- history of relevant orthostatic hypotension, fainting spells or blackouts;
- disease of the central nervous system (such as epilepsy);
- chronic or relevant acute infection; and
- use of medication known to potentially increase or decrease dabigtran exposure.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Otro: Dabigatran etexilate 110 mg
Single dose of Dabigatran etexilate 110 mg po
|
All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session.
Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Pharmacokinetics following a single dose of dabigatran etexilate in hemodialysis patients.
Periodo de tiempo: 0,0.5,1,2,3,4,12,24, and 48 hours post dose following single dabigatran dose
|
Dabigatran plasma concentration following a single dose of dabigatran etexilate in hemodialysis patients
|
0,0.5,1,2,3,4,12,24, and 48 hours post dose following single dabigatran dose
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Fraction of dabigatran in the blood removed by dialysis.
Periodo de tiempo: 0,1,2,3 and 4 hours post dose
|
0,1,2,3 and 4 hours post dose
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: jo-anne wilsoon, PharmD, CDHA Renal Program
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Enfermedades hematológicas
- Trastornos hemorrágicos
- Trastornos hemostáticos
- Trastornos de la coagulación de la sangre
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Inhibidores de la proteasa
- Antitrombinas
- Inhibidores de la serina proteinasa
- Anticoagulantes
- Dabigatrán
Otros números de identificación del estudio
- Dabigatran Hemodialysis 2012
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Dabigatran Etexilate 110 mg
-
Nocion TherapeuticsTerminado
-
Section for Affective Disorders; Northern Stockholm...Karolinska Institutet; Vastra Gotaland Region; Region Örebro County; Uppsala University...Reclutamiento
-
Catherine ShuTerminadoCáncer de pulmón de células pequeñas en estadio extensoEstados Unidos
-
mariam hamoudaTerminadoGlositis migratoria benignaEgipto
-
University Hospital, GhentTerminadoPacientes en estado críticoBélgica
-
Population Health Research InstituteHamilton Health Sciences CorporationTerminadoFibrilación auricular | Tromboembolismo venosoCanadá
-
Cancer Institute and Hospital, Chinese Academy...Aún no reclutando
-
University of AlbertaTerminadoAtaque isquémico transitorio | Accidente cerebrovascular isquémico menorCanadá
-
Boehringer IngelheimTerminadoCateterismo cardíacoPaíses Bajos
-
Hospital Ana NeryTerminado